Integrating Advanced Practice Providers into Genetic Testing Protocols
Advanced practice providers are assuming a central role in the genetic testing workflows of modern urology practices. As diagnostic tools move beyond research settings and into standard clinical care, the demand for clear patient communication and efficient testing logistics continues to grow. Mary Dunn, MSN, RN, NP-C, OCN, from the University of North Carolina, Chapel Hill, emphasizes that these providers function as critical touchpoints for patients navigating complex medical decisions.
Clinicians often face time constraints when managing heavy patient volumes. APPs provide the necessary bandwidth to initiate essential conversations about germline and somatic testing. These discussions are not limited to medical explanations. They cover the difference between hereditary and tumor-based testing, the specific rationale for testing in a given case, and the practical steps required to complete the procedure. By handling these early interactions, APPs ensure that patients arrive at a baseline understanding before moving to more intensive treatment planning.
Managing Patient Communication and Result Delivery
Delivering test results requires a distinct clinical approach that balances clarity with emotional intelligence. Positive findings carry weight beyond the individual patient, as they often imply risks for family members. Dunn advocates for a structured approach that avoids relying solely on digital health portals. Instead, she prefers in-person discussions or telephone calls for communicating results that require careful follow-up.
This method allows for real-time clarification. Patients often have questions about the implications of their results, and the opportunity for immediate dialogue helps mitigate anxiety. To reinforce these conversations, providers should supply written educational materials that patients can revisit at home. This creates a lasting reference that supports informed decision-making throughout the care process.
The Future of Collaborative Genetic Care
Genetic medicine in urology is moving toward a model where multidisciplinary teams dictate the speed and quality of outcomes. The role of the APP here is to act as a bridge. While they are often the primary point of contact, they also identify when a case exceeds standard testing protocols and requires the specialized expertise of a genetic counselor or a clinical genetics expert.
Looking ahead, the integration of these providers into daily practice will likely increase as therapeutic targets become more common in urologic oncology. The ability to offer consistent, high-quality genetic assessments allows teams to tailor prognosis discussions more accurately. Practitioners should watch for how regional practices refine these referral pipelines, as the goal remains a balance between accessibility and high-level genetic expertise for every patient.